Sino Biopharm gains ground in ADC drug development

Sino Biopharmaceutical Limited (HKEX:1177) has announced significant progress in its development of antibody-drug conjugates (ADCs) for cancer treatment. The National Medical Products Administration (NMPA) of China has granted implied approval for a clinical trial of TQB2101 (ROR1 ADC), designed for advanced malignant tumors. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) shows low expression in normal tissue, but high expression in lung, ovarian and breast cancers. Preclinical data indicates that TQB2101 exhibits anti-tumor activity with a good safety profile. This ADC joins the company's growing portfolio of clinical-stage ADCs.